Ropes & Gray represented FibroGen in the sale of its China subsidiary, Fibrogen China, to AstraZeneca for approximately $160 million. The transaction was announced in a Feb. 20 press release.
FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia.
The Ropes & Gray team that advised Fibrogen was led by mergers & acquisitions partner Arthur Mok and associate Reed Harasimowicz, litigation & enforcement partner Lisa Kaltenbrunner, tax partner Benjamin Rogers, private equity partner Oliver Nip, IP transactions partner Geoffrey Lin, executive compensation & employee benefits partner Ellen Sueda, and life sciences partner Katherine Wang.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.